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Thrombospondin-1Ca2+ elevation is essential to platelet activation. STIM1 senses Ca2+ in the endoplasmic reticulum and activates
Orai channels allowing store-operated Ca2+ entry (SOCE). STIM1 has also been reported to be present in the
plasma membrane (PM) with its N-terminal region exposed to the outside medium but its role is not fully
understood. We have examined the effects of the antibody GOK/STIM1, which recognises the N-terminal region
of STIM1, on SOCE, agonist-stimulated Ca2+ entry, surface exposure, in vitro thrombus formation and aggrega-
tion in human platelets. We also determined novel binding partners of STIM1 using proteomics. The dialysed
GOK/STIM1 antibody failed to reduced thapsigargin- and agonist-mediated Ca2+ entry in Fura2-labelled cells.
Using ﬂow cytometry we detect a portion of STIM1 to be surface-exposed. The dialysed GOK/STIM1 antibody
reduced thrombus formation by whole blood on collagen-coated capillaries under ﬂow and platelet aggregation
induced by collagen. In immunoprecipitation experiments followed by proteomic analysis, STIM1 was found to
extract a number of proteins including myosin, DOCK10, thrombospondin-1 and actin. These studies suggest
that PM STIM1may facilitate platelet activation by collagen through novel interactions at the plasmamembrane
while the essential Ca2+-sensing role of STIM1 is served by the protein in the ER.
© 2013 Elsevier Inc. All rights reserved.1. Introduction
Platelet activation is essential in haemostasis and plays a key role in
thrombosis. Important for platelet activation is Ca2+ elevation in the
cytosol, which occurs as a result of release from intracellular stores
and entry from the outside medium [1,41]. Whilst Ca2+ release from
intracellular stores by agonist-induced formation of inositol 1,4,5-
trisphosphate is established, Ca2+ entry mechanisms are less under-
stood. In platelets, three pathways for Ca2+ entry have been identiﬁed.
Platelets express the P2X1 receptor that is a ligand-gated ion channel
for ATP [27]. Ca2+ entry can occur after store depletion (referred to as
store-operated Ca2+ entry [SOCE]) [1,41] and, second messengers
(such as 1,2-diacyl-sn-glycerol [DAG]) may gate plasma membrane
(PM) cation channels such as the transient receptor potential canonical
6 [TRPC6] [17,18].
Recent studies have provided major insights into the mechanisms
and molecular components of SOCE. Stromal interaction molecule 1
(STIM1), a ~80 kDa transmembrane protein abundant in the endoplas-
mic reticulum (ER), is the Ca2+ sensor of the ER. Upon store depletion,1; SOCE, store operated Ca2+
rane; TG, thapsigargin; OAG,
or potential canonical.
ghts reserved.Ca2+ comes off its EF hand domain and the protein oligomerises and
translocates to punctae to activate PM cation entry channels [25,34].
Orai1, which belongs to a family of Orai proteins (Orai1, Orai2 and
Orai3), is established as the Ca2+ release activated Ca2+ (CRAC) channel
of haematopoietic cells [10,42]. Recently, both STIM1 and Orai1 have
been shown to be essential for SOCE in platelets as the absence of either
in mouse platelets leads to lack of SOCE, greatly reduced agonist-
stimulated Ca2+ entry and a marked protection against thrombus
formation in a number of in vivomodels of thrombosis butwhilst aggre-
gation responses are largelymaintained [7,12,40]. The STIM1–Orai1 axis
may thus represent a major target for anti-thrombotic therapy [2].
STIM1was originally identiﬁed as a PMprotein involved in pre-B cell
interaction and as a regulator of cell growth [29,31,43]. An antibody
recognising the N-terminal domain of STIM1 (GOK/STIM1) has been re-
ported to inhibit SOCE in intact HEK-293 cells [35] and in intact platelets
[26] suggesting that some STIM1 is present in the PMwith the EF-hand
domain exposed on the outer surface. However in other studies STIM1
has been proposed not to be expressed in the PM, but to translocate to
regions of juxtaposition to the PM upon activation [25]. To examine
these issues we have studied possible functions of surface-exposed
STIM1 in human platelets. We report that, the puriﬁed STIM1 antibody
failed to inhibit Ca2+ elevation by store depletion and by agonists in
human platelets. However the antibody reduced thrombus formation
by human blood on collagen-coated capillaries under ﬂow and platelet
aggregation to collagen. Proteomic analysis of immunoprecipitated
503A. Ambily et al. / Cellular Signalling 26 (2014) 502–511STIM1 revealed the protein to bind to myosin, actin, DOCK10 and
thrombospondin-1. Our studies suggest that PM STIM1 may take part
in novel interactions at the plasma membrane supporting platelet
aggregation but that SOCE is not essential for aggregation in human
platelets.2. Materials and methods
2.1. Reagents
Unless stated otherwise, reagentswere purchased from SigmaAldrich
(Dorset, UK). The GOK/STIM1 antibody and control mouse IgG2a were
from BD Biosciences (Oxford, UK). PL/IM 430 (used as a control antibody,
recognises SERCA3) and PM6/40 (recognising GP1B) were puriﬁed from
hybridoma cell cultures as previously described [6]. Polyclonal STIM1 an-
tibody recognising a C-terminal epitope was from ProSci (Poway, USA).
IID8 antibody to SERCA 2 was purchased from Abcam (Cambridge, UK).
Myosin-9 and Thrombospondin-1 antibodies were from Santa Cruz
(USA). BTP-2 (N-(4-[3,5-bis(triﬂuoromethyl)-1H-1yl]phenyl)-4-methyl-
1,2,3-thiodiazole-5-carboxamide) was from Calbiochem (Nottingham,
UK). LOE-908 (3,4-dihydro-6,7-dimethoxy-a-phenyl-N,N-bis[2-(2,3,4-
trimethoxyphenyl)ethyl]-1-isoquinolineacetamide hydrochloride) was
from Tocris (Bristol, UK).
Dialysis membranes (Membra-Cel MD10-14 × 100 CLR) were
boiled for 10 min in 2% sodium bicarbonate containing 0.05% EDTA
followed by boiling in double-distilled water for 5 min. Antibodies
were dialysed in 2 changes of ice cold PBS overnight at 4 °C.2.2. Human platelet preparation, Ca2+ measurements, aggregation and
ﬂow cytometry studies
Bloodwas taken fromhealthy volunteers as stipulated by local ethical
guidelines into one tenth volume 3.2% trisodium citrate. Platelet rich
plasma (PRP) was prepared by centrifugation of the blood at 200 ×g
for 20 min. Fura2-AM labelling was carried out in PRP as previously
described [17] and the platelets were re-suspended at a cell count
of 8 × 108 cells/ml in HEPES-Tyrode buffer consisting of 10 mM
Hepes, 140 mM NaCl, 5 mM KCl, 1 mM MgCl2, 5 mM glucose,
0.42 mM NaH2PO4·H2O, 12 mM NaHCO3, 0.2 mM EGTA, 10 μM indo-
methacin and 1 U/ml apyrase. Cells were incubated for 30 min at 37 °C
in the presence of 5 μg/ml of either GOK/STIM1 antibody, or control
IgG (PL/IM430 in PBS) [6] or vehicle control (equal volume of PBS),
followed by dilution to 2 × 108 cells/ml in HEPES-Tyrode buffer without
EGTA and apyrase. Fura2 emission upon excitation of the cells at 340 and
380 nmwas recorded using a Cairn Optoscan spectroﬂuorimeter. Traces
shown are representative of experiments on at least three separate
platelet preparations.
For aggregation studies, platelet suspensions were incubated as
above with 10 μg/ml GOK/STIM1 or control IgG2a dialysed antibodies.
Platelet suspensions diluted to 2 × 108 cells/ml were stimulated in a
Payton dual channel aggregometer (or Biodata Pap4) in the presence
of 1 mM Ca2+ for at least 4 min. For experiments involving BTP2 and
LOE908, platelets were resuspended at 2 × 108 cells/ml and reagents
added as indicated in the ﬁgures.
For analysis of PM STIM1, platelets were resuspended at
1 × 108 cells/ml and incubated at 37 °C with and without thapsigargin
(TG, 10 μM) for 3 min. Reactions were stopped with ice cold EDTA
(10 mM ﬁnal). The cells were then incubated with primary antibody
at 5 μg/ml for 1 h on a rocker followed by ﬂuorescent secondary
antibody (goat anti-mouse Alexa 488, 1/50 dilution of stock containing
0.5 mg/ml) for 1 h in the dark. Cellswere ﬁxedwith 1% p-formaldehyde
and kept in the dark until analysed by ﬂow cytometry using a Beckman
Coulter Cytomics FC500 MPL ﬂow cytometer. 10,000 events were
analysed for surface labelling.2.3. Western blotting
Samples of platelet lysates (after lysis of 1 × 109 cells/ml) or immu-
noprecipitations in Laemmli sample buffer, were subjected to electro-
phoresis using 7% gels and separated proteins were transferred onto
PVDF membrane by semi-dry blotting as previously described [17].
The membranes were blocked overnight, washed 4 times, incubated
with primary antibody (1/250 dilution for GOK/STIM1 or as indicated
in the ﬁg. legends) for at least 1 h, washed, incubated with secondary
antibody (e.g. goat anti-mouse usually 1/10,000) conjugated to HRP,
washed again and proteins detected using ECL reagents as described
[17]. Samples of hTRPC6, hTRPC3, hTRPC1, mTRPC4, mTRPC5, and
mTRPC7 over-expressed in QBI(HEK)-293 cells and TRPC antibody
preparation and puriﬁcation were prepared as described previously
[17]. Antibodies in rabbits to TRPC3 (A1978) were generated using the
sequence (C)RRRLQKDIEMGMGN and to TRPC7 (1567) using the
sequence (C)LNKDHLRVNKGKDI. A TRPC6 monoclonal (SL-TC6) was
obtained from Novartis, Horsham U.K. Blots shown are typical of at
least three on separate preparations.
2.4. Thrombus formation in whole blood under arterial ﬂow
Formation of thrombi on collagen-coated capillaries was carried out
using a modiﬁcation of the method described by Tucker et al. [36].
Whole blood was incubated with puriﬁed antibodies at 10 μg/ml at
37 °C for 30 min followed by labelling with the ﬂuorescent lipophilic
dye 3,3′-dihexylocarbocyanine iodide (DiOC6; 0.5 ng/ml ﬁnal) in 50%
ethanol (0.05% v/vﬁnal) in the dark at 30 °C for 20 min. Glass capillaries
(Camlab, Cambridge, UK) of dimensions 0.1 mm × 1 mm × 50 mm
were coated with 100 μl of 100 μg/ml collagen in HEPES-Tyrode over-
night at 4 °C. Prior to experiments, the capillaries were blocked with
100 μl of 1% (w/v) protease free BSA for 1 h followed by ﬂushing with
HEPES-Tyrode buffer. The antibody-treated blood was then perfused
over the collagen-coated capillaries at a shear rate of 1000 s−1 for
4 min at room temperature. The formed thrombi were then washed
with Hepes-Tyrode buffer at the same shear rate for 8 min to remove
unattached cells and the capillaries were analysed using a Leica
DMIRE2 inverted confocal microscope (N PLANL 20×/0.4 objective;
with 0 to 2 mm correction). Five random views were selected and
Z-stack images taken from the matrix surface progressing through the
thrombi every 2 μm and analysed using TCS SP2 software to calculate
thrombus volume.
2.5. Proteomic analysis of immunoprecipitated extracts of STIM1 by liquid
chromatography–mass spectrometry/mass spectrometry (LC–MS/MS)
Platelets were resuspended at 1 × 109 cells/ml and incubated with
TG for 1 min followed by lysis in equal volume of RIPA lysis buffer and
immunoprecipitation as described in [39]. Extracted samples were run
on 5–15% gradient SDS-PAGE gels followed by Colloidal Coomassie
staining (see Results). Segments containing visible bands and clear
areas were exposed to in-gel reduction, alkylation and digestion with
trypsin using standard protocols. Peptides were extracted from the gel
pieces by a series of acetonitrile and aqueous washes. The extract was
lyophilised, resuspended in 23 μl of 50 mM ammonium bicarbonate
and analysed by LC–MS/MS using an Ultimate LC system (Dionex, UK).
Peptides were resolved using 75 μm C18 PepMap column. A 60 minute
gradient of acetonitrile in 0.05% formic acid was delivered to elute the
peptides at a ﬂow rate of 200 nl/min. Peptides were ionised by
electrospray ionisation using a Z-spray source ﬁtted to a QTof-micro
(Waters Corp.). The MS/MS analyses were conducted using collision
energy proﬁles based on the mass-to-charge ratio (m/z) and the charge
state of the peptide.
The mass spectral data was processed using ProteinLynx Global
Server v2.2.5, and the Swiss Prot database using Mascot software v2.2
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for all the peptides included in the results.
2.6. Statistical analysis
P-values were calculated using GraphPad Prism software.
3. Results
3.1. Puriﬁed GOK/STIM1 antibody does not inhibit Ca2+ entry into platelets
We have recently reported that sodium azide that is present in
almost all commercial antibody preparations will inhibit Ca2+ entry
into human platelets [39]. To examine the effects of the GOK/STIM1
antibody we dialysed the GOK/STIM1 antibody against two changes of
PBS overnight and tested the antibody at a dose of 5 μg/ml (equivalent
to 1/14 dilution). This was compared with a control puriﬁed antibody
preparation (PL/IM430), PBS and sodium azide at a concentration of
0.006% (calculated ﬁnal concentration of azide that would be presentA
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Fig. 1. PuriﬁedGOK/STIM1 antibody does not inhibit Ca2+ entry in human platelets. Fura2 label
followedby analysis of Ca2+ elevation using 340/380 nmratioﬂuorescence. A. Platelets stimulat
Ca2+ addition to measure Ca2+ entry. Black lines indicate incubation of platelets with control
sodium azide. Dotted lines in A and B indicate recordings in the absence of agonist addition bu
presence of PBS = 0.749 ± 0.004 [n = 3], in the presence of dialysed GOK/STIM1 = 0.714
P = 0.038; ]. B. Responses in platelets stimulated by 1 μg/ml convulxin (CvX). With Ca2+ r
ratio value for Ca2+ entry in the presence of PBS = 0.57 ± 0.062 [n = 3], in the presence of d
of sodium azide = 0.323 ± 0.031 [n = 3, P = 0.011; ]. C. Platelets stimulated by 3 μM TG
Unﬁlled black bars reﬂect PBS control, red bars in the presence of GOK/STIM1 antibody and blu
to controls. Values are frommeans ± SEM (n = 3). E. Western blotting analysis of STIM1 in pl
GOK/STIM1 antibody (lane 2; 1/250 dilution). All lanes had 50 μg protein; lanes 3 and 4 were
platelet lysates by 2 dilutions of un-puriﬁed and dialysed GOK/STIM1 antibodies by western
recognition of SERCA 2 by IID8. P values were not signiﬁcant.if the neat antibody was used in the experiments). Experiments were
carried using the Ca2+ add back protocol where platelets were incubat-
ed in 100 μM EGTA, then agonist 3 min later to examine Ca2+ release
from stores followed by the addition of 1 mM Ca2+ 3 min later to
examine Ca2+ entry. The PL/IM430 control antibody (at 5 μg/ml) had
no effect on basal Ca2+ levels, Ca2+ release from stores or Ca2+ entry
by agonists compared with platelets incubated with PBS (thus only
traces with PBS are shown). In Fig. 1 (A,B,C) control traces in black rep-
resent agonist induced responses in the presence of PBS or PL/IM430.
Incubation of platelets with 5 μg/ml GOK/STIM1 antibody showed no
effect on thrombin- (1.25 U/ml) or convulxin- (1 μg/ml) or thapsigargin
(TG, 3 μM) induced Ca2+ release or Ca2+ entry. When lower doses of
thrombin were used at 0.3 and 0.6 U/ml there was also no signiﬁcant
effect in the presence of the GOK/STIM1 antibody (results not shown).
Sodium azide however, was effective at inhibiting thrombin-
and convulxin-induced Ca2+ entry (by 38% [P = 0.038] and 43%
[P = 0.011]) respectively (blue traces in Fig. 1 and bar charts Fig. 1D). A
negative trend was observed against convulxin-stimulated Ca2+ release
with sodium azide but was not signiﬁcant. The dialysed GOK/STIM1EGTA TG Ca2+
* ** ***
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responses but again failed to reduce Ca2+ entry signiﬁcantly (results not
shown). However, TG-stimulated Ca2+ entry was inhibited by sodium
azide by 26% (P = 0.001) (Fig. 1).
We tested if dialysis of the GOK/STIM1 antibody may have altered
the recognition of STIM1. Fig. 1E shows detection of STIM1 in Western
blots using 2 dilutions of dialysed or un-dialysed antibody expressed
as a ratio of the detection of SERCA 2 (used as control). No signiﬁcant
difference in detection of STIM1 was found (Fig. 1F). As the effects onA
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0.4% ± 0.15, P = 0.025) vs PL/IM430 (% cells stained 0.5% ± 0.06). C. Bar chart showing% cellsw
control. D. Bar chart showing effects of TG treatment (10 μM) on surface expression of STIM1 (G
TG treatments for each set (n = 3).Ca2+ entry were carried out at 1/14 dilution, the lack of inhibition by
the puriﬁed antibody on Ca2+ entry was not due to loss of STIM1
recognition.
3.2. Surface expression of STIM1 by ﬂow cytometry
We next sought to determine the surface exposure of platelet STIM1
by ﬂow cytometry of bound antibodies. Fig. 2 (A + B) shows typical
gating of 10,000 platelets separated by forward and side scatter andGOK/STIM1
B
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506 A. Ambily et al. / Cellular Signalling 26 (2014) 502–511the detection of platelets labelled with the dialysed GOK/STIM1
antibody. Bar charts show% of platelets labelledwith the corresponding
antibodies. Platelets incubated with PM6/40 (an antibody to GPIB)
show labelling of 90% of the platelet population (Fig. 2C). With the
control PL/IM430 and secondary antibodies less than 1% of cells were
labelled, whereas with the GOK/STIM1 antibody the degree of labelling
was approximately 13% (P = 0.0026 vs secondary antibody control;
P = 0.025 vs PL/IM 430). Between donors there was a larger variation
in range (from 5% to 30%) of STIM1 surface expression than for PL/IM
430 (variation 0.5–0.8%) or for PM6/40 (variation 85–99%). Following
stimulation with 10 μM TG, no signiﬁcant difference was observed in
the labelling of platelets with the GOK/STIM1 antibody, suggesting no
further insertion of STIM1 into the plasmamembrane upon store deple-
tion. Mean ﬂuorescence intensity values of the platelets were also not
different between resting or TG-treated platelets labelled with the
GOK/STIM1 antibody (results not shown).3.3. Effects of the GOK/STIM1 antibody on thrombus formation on collagen
under ﬂow
We then sought to determine if PM STIM1played any role in amodel
of platelet-mediated thrombus formation on collagen under ﬂow that
has been previously characterised [36]. Whole blood incubated with
antibodies and labelled with DiOC6 was perfused through a collagen-
coated capillary at a shear rate of 1000 s−1 and the resulting thrombi
analysed by microscopy. Fig. 3 shows typical images of thrombi formed
after 4 min perfusion in the presence of 10 μg/ml control antibody,
or GOK/STIM1 or PM6/40. The GOK/STIM1 antibody showed a 26%
inhibition of mean thrombus volume (P = 0.049, n = 5) (Fig. 4). The
presence of the PM6/40 antibody reduced mean thrombus volume by
90% (P = 0.028; n = 3) conﬁrming the total requirement of GPIB in
mediating platelet adhesion to collagen under shear and validating the
methodology of using antibody reagents in this system.Fig. 3.GOK/STIM1 reduces thrombus formation on collagen coated capillary under ﬂow. Upper
incubated with control puriﬁed antibody (PL/IM430; upper left), dialysed GOK/STIM1 antibody
thrombus volume after 4 min perfusion at a shear rate of 1000 s−1 (GOK/STIM1 vs control P =3.4. Effects of GOK/STIM1 antibody, the SOCE inhibitor BTP2 and non-SOCE
inhibitor LOE908 on platelet aggregation
We then analysed effects on platelet aggregation mediated by TG
(SOCE), 1-Oleoyl-2-acetyl-sn-glycerol (OAG; a non-SOCE activator), col-
lagen and thrombin. We have shown that TG induces platelet aggrega-
tion by depletion of intracellular stores, and indomethacin partially
reduces this response [3]. In the presence of indomethacin, the aggrega-
tion induced by TG is dependent on the presence of extracellular Ca2+.
We tested the effects of BTP2, a recently described inhibitor of SOCE that
is speciﬁc at up to 1 μM but can reduce non-SOCE induced by OAG at
10 μM and above [16]. BTP2 inhibited TG-induced platelet aggregation
in a dose-related manner with 1 μM reducing aggregation by 70%
(P = 0.0007; Fig. 4A). At 1 μM, BTP2 did not signiﬁcantly affect 60 μM
OAG-induced aggregation but at 10 μMand above an inhibitionwas ob-
served. We also tested the non-SOCE inhibitor LOE908, reported to in-
hibit Ca2+ entry mediated by OAG which is an activator of TRPC6 and
TRPC3 [14–17]. LOE908 at 10 (or 30) μM did not affect TG-induced
platelet aggregation but almost completely reduced OAG-induced
platelet aggregation (Fig. 4C, D). Thus BTP2 (at selective concentrations)
and LOE908 could be used with caution to inhibit SOCE and non-SOCE
respectively. The dialysed GOK/STIM1 antibody at 10 μg/ml (compared
to a dialysed IgG2a [or PL/IM430, not shown]), did not inhibit aggrega-
tion induced by 5 μMTG (Fig. 4E, F) nor did it induce any response on its
own (not shown).
These reagents were then tested against moderate concentrations of
thrombin and collagen. The GOK/STIM1 antibody did not inhibit the
shape change or the aggregation response by 0.5 U/ml thrombin
(Fig. 4G), nor were these responses affected by the presence of 1 μM
BTP2 or 10 μM LOE908 or both together (results not shown) (10 μM
BTP2 did reduce thrombin-stimulated platelet aggregation but the ef-
fects could not be ascribed to inhibition of SOCE—results not shown).
However against 10 μg/ml collagen, the GOK/STIM1 antibody caused a
reduction in the aggregation by 23% (P = 0.0016; see Fig. 4G) with nopanel, representative images of thrombi formed on collagen coated capillaries using blood
(centre) and dialysed GP1B antibody (PM6/40) (upper right). Bar chart, analysis of mean
0.048; n = 5; PM6/40 vs control P = 0.028; n = 3).
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507A. Ambily et al. / Cellular Signalling 26 (2014) 502–511effect if aggregationwas induced by higher 20 μg/ml collagen concentra-
tion. BTP2 at 1 μM did not affect the aggregation recorded with either
10 or 15 μg/ml collagen; however LOE908 did reduce the extent ofaggregation by 36% (P = 0.001; Fig. 4H), suggesting that the non-SOCE
pathway contributed signiﬁcantly to the aggregation response to
collagen.
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in thrombus formation on a collagen-coated surface and collagen-
induced platelet aggregation that may be independent of SOCE.
To test if PM STIM1 interacted with components of the non-SOCE path-
way we imunoprecipitated STIM1 to examine if TRPC6 or TRPC3 were
co-immunoprecipitated. Fig. 5A shows that STIM1 can be avidly
immunoprecipitated from resting and platelets treated with thrombin,
CRP and TG using a polyclonal STIM1-C terminal recognising antibody
from ProSci Inc. (USA). However when the immunprecipitates were
immunoblottedwith TRPC6 or TRPC3 antibodies therewas no detection
of these channels (Fig. 5B, C). TRPC6 and TRPC3 overexpressed in QBI-
(HEK)-293 cells served as positive controls for detection. We were
also unable to detect any co-immunopreciptation of TRPC4, TRPC5 or
TRPC7 with STIM1 (results not shown). This suggests that PM STIM1
may modulate collagen induced platelet aggregation via a novel
mechanism.3.5. Identiﬁcation of novel binding partners of STIM1 in human platelets
To search for potential binding partners of STIM1 on the platelet
surface we carried out a proteomic analysis of immunoprecipitated
STIM1 from TG-treated platelets. The SDS-PAGE gel revealed
protein bands additional to the antibody reagents that were visible
with Coomassie staining (Fig. 6A). Proteins with 2 or more positive
peptide hits returned from proteomic analysis are listed (Table 1).
These include myosin-9, dedicator of cytokinesis protein-10
(DOCK10), thrombospondin-1 (TSP-1) and actin. All four proteins
were conﬁrmed to be present in platelet lysates bywestern blotting (re-
sults not shown). STIM1 peptides covered 38% of the sequence
suggesting good immunoprecipitation. Coverage for myosin-9 was 3%,
for DOCK10 1%, for TSP-1 11% and for actin 16%. As TSP-1 is a secretedCa2+ + + +
Fig. 5. STIM1 does not co-immunoprecipitate TRPC6 or TRPC3 in human platelets. Platelets (1
Immunoprecipitation was carried out with C terminal polyclonal antibody to STIM1, split into
with GOK/STIM1 (1/250 dilution), anti-TRPC6 (SL-TC6; 1/500 dilution) and anti-TRPC3 (A1
hTRPC3 or hTRPC6 over-expressed in QBI-293 cells for positive identiﬁcation of the respectiveprotein of alpha granules and is known to bind to the plasma
membrane; it may bind to PM STIM1. In contrast myosin-9, actin and
DOCK10 are intracellular proteins and depending on their location
may bind to ER or PM STIM1. We sought to conﬁrm the co-
immunoprecipitation using Western blotting. Fig. 6B shows that TSP-1
and myosin-9 could be detected as co-immunoprecipitated proteins
with STIM1 from platelet lysates conﬁrming them to be potential
binding partners for STIM1.4. Discussion
This study reports for the ﬁrst time a potential supporting role of PM
STIM1 in human platelet aggregation induced by collagen which is dis-
tinct from the SOCE role of STIM1 at the ER, andmay involve interaction
with the secreted protein TSP-1 in addition to cytosolic components
such as DOCK10, myosin, actin and other components.
Although STIM1 in the endoplasmic reticulum is essential for
sensing Ca2+ depletion in the ER through the Ca2+-binding N-terminal
region [25,34] a fraction of STIM1 has been recognised to be expressed
in the PM and suggested to participate in SOCE [35]. However, over-
expression of N-terminally tagged STIM1 (tomonitor STIM1 localisation)
suggests that STIM1 does not insert into the PM [5,25]. Moreover, substi-
tution of endogenous STIM1with N-terminally tagged GFP-STIM1 in DT-
40 cells fully supports SOCE, suggesting a non-essential role for PMSTIM1
in Ca2+ entry [5]. In platelets Lopez et al. reported the presence of STIM1
in the plasma membrane and a doubling of the surface expression with
TG in a Ca2+ independentmanner [26]. However, the same group subse-
quently reported a 44% (at 10 s) and 28% (at 1 min) increase dependent
on extracellular Ca2+ [23]. In our studies an increase of STIM1 surface la-
belling upon store depletion was not observed and we favour migration
of STIM1 into punctae as a mechanism to induce Ca2+ entry rather than +
× 109 cells/ml) were treated with reagents as indicated for 1 min and lysates prepared.
three and subjected to western blotting analysis in parallel. Immunoblots were probed
978; 1/200 dilution) antibodies. QBI + hTRPC3 and QBI − hTRPC6 reﬂect lysates from
channels. Blots are typical of three separate determinations.
A B
225
150
102
76
52
38
31
17
Fig. 6. Immunoprecipitation of STIM1 for proteomic analysis and western blots. A. STIM1
was immunoprecipitated using an antibody recognising the C terminus of STIM1 from
TG treated platelets (1 min) with the SDS-PAGE gels stained by Colloidal Coomassie
stain (TG pla. Lane 3). Lane 1 mm = molecular markers; lane 2 Ab con = antibody
reagent control including protein G; lane 3 STIM1 immunoprecipitate. Arrows reﬂect
prominent bands immunoprecipitated by the STIM1 antibody. Bands and clear areas of
the gel were used for peptide identiﬁcation (see Materials and methods). Numbers
on the left reﬂect the size of molecular markers in kDa. B. Co-immunoprecipitation of
TSP1 and myosin with STIM1 from platelet lysates. WB-STIM1 probed with GOK/STIM1
(1/250 dilution), TSP-1 (1/200 dilution) and Myosin (1/1000 dilution) antibodies as
indicated in Materials and methods. Ab control lane reﬂects a total reagent control with
antibody, protein G etc. but without platelets.
509A. Ambily et al. / Cellular Signalling 26 (2014) 502–511further insertion into the PM, as suggested by others [25]. Regarding a
role in Ca2+ entry the un-puriﬁed GOK/STIM1 antibody has been report-
ed to inhibit Ca2+ entry to various extents in various cells. Mignen et al.
[30] reported that arachidonate regulated Ca2+ (ARC) channels were
more inhibited than CRAC channels. With platelets, Lopez et al. reported
the neat un-puriﬁedGOK/STIM1antibody (at 1 μg/ml vs no treatment) to
inhibit Ca2+ entry by 36% suggesting a supporting role [26]. However
they recently suggest that PM STIM1 may mediate the inactivation of
SOCE by extracellular Ca2+ [23] and in an over-expression system sug-
gesting that the EF hand domain and lysine rich domains are important
in this function [22]. Our study reporting no effect on SOCE by the
dialysed STIM1 antibody and the inhibition of SOCE by sodiumazide, sug-
gests caution with previous studies as the preservatives themselves may
exert effects. Further concentrations of preservatives may vary between
batches of the same or different antibody preparations. The sodium
azide reduced cation entrymediated by TG, thrombin and convulxin, im-
plicating azide to inhibit a common point in the SOCE pathway. In
addition to other effects that may be relevant, sodium azide can inhibit
complex IV of mitochondria [38] and inhibition of mitochondrial
function has been shown to reduce Ca2+ entry in many cells [19]. We
did not examine the mechanism of azide action further as our purpose
was to examine STIM1 function.
In our hands, surface binding of the STIM1 antibody reduced
collagen-induced aggregation and mean thrombi volume formed on
collagen-coated surfaces under ﬂow. This suggests for the ﬁrst time an
extracellular role for STIM1 in a human platelet adhesion event which
is independent of an effect on SOCE. On collagen-coated surfaces
under ﬂow, platelet attaches initially via the GP1B complex, becomesactivated and thrombus formation ensues with further platelet recruit-
ment to the adherent cells. Many adhesive receptors such as GPIB, GPVI,
α2β1, and αIIbβ3 and signalling components have been shown to be
important [21]. Antibodies to GP1B are particularly potent inhibitors
of thrombus formation as shown with PM6/40. Engagement of PM
STIM1 by the GOK/STIM1 antibody did not lead to a decrease of throm-
bus numbers but of thrombus volume, suggesting that the initial plate-
let attachment was not affected. The decrease of mean thrombus
volume may therefore indicate a role for PM STIM1 in platelet–platelet
interaction.
The effect of the GOK/STIM1 antibody on collagen-induced platelet
responses supports the ﬁndings of others on STIM1-deﬁcient mouse
platelets which show reduced Ca2+ entry to all agonists, but effects on
aggregation responses to only collagen and CRP (not to ADP or throm-
bin) and reduced thrombus formation on collagen under ﬂow [40].
Mouse platelets expressing an EF-handmutation of STIM1 (Sax) exhibit
increased basal Ca2+ entry, and again reduced responses to agonists
involving ITAM receptors but not G-protein-linked receptors suggesting
a role of STIM1 in ITAM signalling [12].Why ITAM signalling is preferen-
tially effected by alterations in STIM1 is not known but may reﬂect a
complex interaction of STIM1 with the GPVI signalling pathway that
may include CLP36 which has been identiﬁed as a negative regulator
of this pathway [13] and the proteins identiﬁed in this study. Interest-
ingly, ADP- and thrombin-induced platelet aggregation is also normal
in mouse platelets absent of Orai1 (clearly suggesting that SOCE is not
required for this response [7,40]) in platelets absent of TRPC1[39] or
TRPC6 [32] (suggesting that non-SOCE is also not required). Our ﬁnding
that in human platelets BTP2 and LOE did not affect aggregation to
thrombin supports the mouse studies. However this data is in contrast
to work reported by Galan et al. where electroporation of the GOK/
STIM1 or an anti-Orai1 antibody into human platelets inhibited ADP
and thrombin induced platelet aggregation. Extracellular application
of the GOK/STIM1 or an anti-TRPC1 antibody was also suggested to
inhibit aggregation suggesting an interaction of PM STIM1, Orai1 and
TRPC1 [11]. The reasons for the discrepancies are unclear [1,28]. Meth-
odologically we have reported that electroporation of platelets allows
free movement of molecules of less than 1000 Da across the platelet
PM with no loss of cytosolic proteins [4,39] which is in contrast to the
Galan study where a 150,000 Da antibody molecule is reported to gain
access into the cytosol of platelets without loss of cytosolic proteins
[11]. Additionally, we have been unable to conﬁrm an interaction of
STIM1 with TRPC1 in human or mouse platelets [39] nor with any
other TRPC channel in human platelets by proteomics or Western
blotting. Therefore we suggest the reduction in collagen induced aggre-
gation by the STIM1 antibody and by the non-SOCE inhibitor LOE908 to
be via distinct pathways.
As PM STIM1 has an EF-hand and a SAM domain facing the extracel-
lular medium, PM STIM1 may take part in interactions involving other
surface proteins. Our proteomic analysis of STIM1 pull-down extracts
revealed novel binding partners of STIM1. Myosin-9 and actin are
intracellular proteins involvedwithmobility and structural organisation
of intracellular organelles and proteins. Binding to these cytoskeletal
components may aid the membrane mobility of STIM1 during re-
organisation into punctae after store depletion. The signiﬁcance of
STIM1 interaction with DOCK10 requires further study. The expression
of DOCK10 in platelets was conﬁrmed by western blotting (results not
shown) and in a proteomic screen by Burkhart et al. [8]. DOCK10 is a
known activator of cdc42 which is implicated in cell motility and
lamellipodia formation. The observed co-immunoprecipitation of
STIM1 with TSP-1 is of particular interest. TSP-1 has been associated
with a number of stimulatory functions and reported to bind to surface
proteins including CD36, CD47,β1, andβ3 subunits of integrins and also
to collagen itself. TSP-1 promotes aggregation [9,37] and antagonises
NO and cAMPmediated effects in many cells including platelets though
the pathways are yet to be fully established [20,33]. Interestingly, a
patient was described whose platelets aggregated to several agonists
Table 1
Analysis of STIM1 immunoprecipitations by proteomics. Only proteins with 2 or more peptide identiﬁcations are shown.
Protein ID and gene Calculated MW (Da) No. of peptides matched % cov. Peptide mass (Mr) Peptide sequences identiﬁed
Myosin-9; MYH9_HUMAN
Myosin-9, non-muscle. P35579
226,392 4 3% 1192.6088 ALELDSNLYR
1868.9592 ANLQIDQINTDLNLER
3016.2616 DLGEELEALKTELEDTLDSTAAQQELR
1997.0541 KANLQIDQINTDLNLER
Dedicator of cytokinesis protein (DOCK)10; DOC10_HUMAN
Dedicator of cytokinesis protein 10. Q96BY6
249,154 2 1% 1102.5982 AVSQLIADAGIGGSR
1413.7576 LTGLSEISQR
Thrombospondin-1. TSP1_HUMAN
Thrombospondin-1. P07996
129,300 10 11% 1206.6245 SITLFVQEDR
1863.9037 MENAELDVPIQSVFTR
1928.0228 IAKGGVNDNFQGVLQNVR
1615.8067 GGVNDNFQGVLQNVR
1393.7242 FVFGTTPEDILR
2408.1386 DLQAICGISCDELSSMVLELR
1245.6929 TIVTTLQDSIR
1874.8911 FTGSQPFGQGVEHATANK
1594.7376 QVTQSYWDTNPTR
1008.524 AQGYSGLSVK
Stromal interaction molecule—1; STIM1_HUMAN
Stromal interaction molecule 1. Q13586
77,375 19 38% 2031.844 ATGTSSGANSEESTAAEFCR
2272.1158 IDKPLCHSEDEKLSFEAVR
1511.8712 ALDTVLFGPPLLTR
1324.6371 AEQSLHDLQER
1437.8191 TVEVEKVHLEKK
1070.6084 LRDEINLAK
1682.9063 LRDEINLAKQEAQR
1520.747 QKYAEEELEQVR
1264.5935 YAEEELEQVR
1873.8846 ELESHSSWYAPEALQK
2326.0979 NTLFGTFHVAHSSSLDDVDHK
1157.6404 QALSEVTAALR
1605.8335 QRLTEPQHGLGSQR
1321.6739 LTEPQHGLGSQR
1815.7693 DLTHSDSESSLHMSDR
1643.7321 AADEALNAMTSNGSHR
2269.2682 LIEGVHPGSLVEKLPDSPALAK
2345.107 AHSLMELSPSAPPGGSPHLDSSR
1920.845 SHSPSSPDPDTPSPVGDSR
Actin, cytoplasmic; ACTG1_HUMAN
Actin. P63261
41,766 4 16% 1953.178 VAPEEHPVLLTEAPLNPK
1131.5197 GYSFTTTAER
2230.0576 DLYANTVLSGGTTMYPGIADR
1160.6111 EITALAPSTMK
510 A. Ambily et al. / Cellular Signalling 26 (2014) 502–511except collagen andwere found to lack GP1b and TSP-1 [24]. Re-addition
of TSP-1 to the in vitro incubations restored the platelet response to colla-
gen [24]. From our results we can hypothesise that PM STIM1 may bind
TSP-1 and enhance GPVI signalling. Further a potential TSP-1, STIM1
and CLP36 interaction that may relieve the negative modulation of
CLP36 on GPVI signalling is worthy of detailed study. In summary, this
work suggests that PM STIM1 may play an important role in facilitating
platelet activation by an interaction with surface-binding proteins that
include TSP-1 in addition to intracellular components involved with
collagen induced signalling. Further studies are required to elucidate the
complex mechanisms involved.
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